Stimulation of the Epithelial Na+ Channel in Renal Principal Cells by Gs-Coupled Designer Receptors Exclusively Activated by Designer Drugs

被引:1
|
作者
Soares, Antonio G. [1 ]
Contreras, Jorge [1 ]
Archer, Crystal R. [1 ]
Mironova, Elena [1 ]
Berdeaux, Rebecca [2 ]
Stockand, James D. [1 ]
Abd El-Aziz, Tarek Mohamed [1 ,3 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Integrat Physiol, San Antonio, TX 78229 USA
[2] Univ Texas Hlth Sci Ctr Houston, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA
[3] Minia Univ, Fac Sci, Zool Dept, Al Minya, Egypt
基金
美国国家卫生研究院;
关键词
vasopressin; sodium excretion; sodium transport; hypertension; epithelial sodium channel; COLLECTING DUCT; SODIUM-CHANNEL; VASOPRESSIN; ENAC; EXPRESSION; EXCRETION; CAMP; PHOSPHORYLATION; CONTRIBUTES; KNOCKOUT;
D O I
10.3389/fphys.2021.725782
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The activity of the Epithelial Na+ Channel (ENaC) in renal principal cells (PC) fine-tunes sodium excretion and consequently, affects blood pressure. The Gs-adenylyl cyclase-cAMP signal transduction pathway is believed to play a central role in the normal control of ENaC activity in PCs. The current study quantifies the importance of this signaling pathway to the regulation of ENaC activity in vivo using a knock-in mouse that has conditional expression of Gs-DREADD (designer receptors exclusively activated by designer drugs; GsD) in renal PCs. The GsD mouse also contains a cAMP response element-luciferase reporter transgene for non-invasive bioluminescence monitoring of cAMP signaling. Clozapine N-oxide (CNO) was used to selectively and temporally stimulate GsD. Treatment with CNO significantly increased luciferase bioluminescence in the kidneys of PC-specific GsD but not control mice. CNO also significantly increased the activity of ENaC in principal cells in PC-specific GsD mice compared to untreated knock-in mice and CNO treated littermate controls. The cell permeable cAMP analog, 8-(4-chlorophenylthio)adenosine 3 ',5 '-cyclic monophosphate, significantly increased the activity and expression in the plasma membrane of recombinant ENaC expressed in CHO and COS-7 cells, respectively. Treatment of PC-specific GsD mice with CNO rapidly and significantly decreased urinary Na+ excretion compared to untreated PC-specific GsD mice and treated littermate controls. This decrease in Na+ excretion in response to CNO in PC-specific GsD mice was similar in magnitude and timing as that induced by the selective vasopressin receptor 2 agonist, desmopressin, in wild type mice. These findings demonstrate for the first time that targeted activation of Gs signaling exclusively in PCs is sufficient to increase ENaC activity and decrease dependent urinary Na+ excretion in live animals.
引用
收藏
页数:10
相关论文
共 4 条
  • [1] Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice
    Zhu, Hu
    Aryal, Dipendra K.
    Olsen, Reid H. J.
    Urban, Daniel J.
    Swearingen, Amanda
    Forbes, Stacy
    Roth, Bryan L.
    Hochgeschwender, Ute
    GENESIS, 2016, 54 (08) : 439 - 446
  • [2] Utilizing Designed Receptors Exclusively Activated by Designer Drug Chemogenetic Tools to Identify Beneficial G Protein-Coupled Receptor Signaling for Fibrosis
    Zhang, Ji
    Vardy, Eyal
    Muise, Eric S.
    Wang, Tzu-Ming
    Visconti, Richard
    Vadlamudi, Ashita
    Pinto, Shirly
    Peier, Andrea M.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2020, 375 (02) : 357 - 366
  • [3] Basolateral P2X4-like receptors regulate the extracellular ATP-stimulated epithelial Na+ channel activity in renal epithelia
    Zhang, Yanjun
    Sanchez, Daniel
    Gorelik, Julia
    Klenerman, David
    Lab, Max
    Edwards, Christopher
    Korchev, Yuri
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2007, 292 (06) : F1734 - F1740
  • [4] Cross talk of cAMP and flavone in regulation of cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel and Na+/K+/2Cl- cotransporter in renal epithelial A6 cells
    Niisato, N
    Nishino, H
    Nishio, K
    Marunaka, Y
    BIOCHEMICAL PHARMACOLOGY, 2004, 67 (04) : 795 - 801